Home > Association : Emerging Companies Council
ACCC's Emerging Companies Council
The Association of Community Cancer Centers' (ACCC) Emerging Companies Council is designed to provide companies with access to up-to-the-minute news and insight into cancer care issues not available through any other professional association.
Your affiliation with ACCC brings you together with decision-makers in the oncology field at hospitals, cancer programs, clinics, and group/private practices across the country. ACCC understands the regulatory, legislative, and policy decisions affecting cancer care and reimbursement. ACCC works on Capitol Hill and elsewhere in Washington, D.C., as an advocate in the cancer care community for cancer centers and oncology practices, including the entire cancer care team of physicians, nurses, administrators, and pharmacists.
Benefits of Membership
Emerging Companies Council members receive a variety of benefits, including recognition through the ACCC network and better visibility with the nationwide cancer care community. Join the Emerging Company Council, and you will:
- Receive timely updates on on current legislative and regulatory issues
- Gain direct contact with key oncology decision makers
- Gain access to a forum in which to communicate their concerns
- Have access to experts in reimbursement, practice management, and health economics.
Members can express their ideas to the oncology community and, in turn, learn what the oncology community thinks about them and their product.
Current ECC Members:
This dynamic content best viewed with Internet Explorer
Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
11080 CirclePoint Road Suite 200
Westminster, Colorado 80020
Tel: 303.426.6262
Allos Therapeutics, Inc., is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.
Folotyn (pralatrexate injection) is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing Folotyn in other potential indications. Allos retains exclusive worldwide rights to Folotyn for all indications. The Company is headquartered in Westminster, Colorado.
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877
Tel: 203.798.9988
Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 47 countries with approximately 39,800 employees. The company is committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.
Boehringer Ingelheim is building on its long-standing research and development capabilities and expertise in several other disease areas (e.g., respiratory, cardiovascular, virology and metabolic disorders), and the strong scientific foundation provided by its research and development centers worldwide. Several years ago, Boehringer Ingelheim started to engage in cancer research in response to the unmet medical needs of patients with cancer and has made advances in understanding cancer biology. With its cancer research and development program, Boehringer Ingelheim is committed to discovering and developing innovative cancer treatments that provide high therapeutic value for patients and healthcare providers. Building on breakthrough science to develop targeted therapies, small molecules and biologics, Boehringer Ingelheim is focusing its research on areas of unmet medical need, including lung, breast, ovarian, colorectal and prostate cancers, as well as lymphomas and leukemias.
Boehringer Ingelheim employs more than 200 scientists in its cancer research facility at the Boehringer Ingelheim Austria Regional Centre in Vienna to discover new cancer medicines. Promising drug candidates are developed by the non-clinical and clinical development organization of Boehringer Ingelheim, representing a team of nearly 400 professionals working in oncology. Their efforts, combined with those of leading experts in cancer research and medicine at universities and cancer hospitals, are focused on developing a range of next-generation therapeutics to combat cancer. Compounds under investigation in oncology focus on three areas: angiogenesis inhibitors, signal transduction inhibitors and cell-cycle kinase inhibitors.
Genomic Health
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Phone: 650.556.9300
Fax: 650.556.1132
Company Information
Genomic Health, a life science company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.
The pioneering work of Genomic Health in molecular diagnostics has led to the Oncotype DX Breast Cancer Assay, a laboratory test that analyzes the expression level of 21 genes in a woman’s breast tumor sample. It is the first and only gene expression test that has demonstrated the ability to predict a patient’s likelihood to benefit from chemotherapy as well as her risk of experiencing a disease recurrence. Oncotype DX is recommended in both the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) clinical practice guidelines, including it in the standard of care for the majority of early-stage breast cancer patients.
At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.
Genomic Health is committed to compliance with applicable federal, state and local statutes and regulations that affect the operation of its business in its role as a provider of healthcare services, in order to conduct its activities with the utmost integrity and in accordance with the law. Genomic Health's compliance program furthers this commitment with internal controls and quality assurance processes that are designed to promote adherence to applicable federal and state laws.
Genzyme Oncology
Genzyme Oncology
Genzyme Oncology
500 Kendall St.
Cambridge, MA 02142
Tel: 617-252-7500
Fax: 617-252-7600
Genzyme is one of the world’s foremost biotechnology companies. Founded in 1981, Genzyme has grown from a small start-up in Boston to a diversified enterprise with over 10,000 employees in locations spanning the globe. Genzyme’s passion, first and foremost, is to patients. Genzyme has translated this passion into products and services that provide significant positive impact on the lives of people with serious diseases, and that meet major unmet medical needs. Genzyme's broad area of focus includes oncology, lysosomal storage disorders, renal disease, orthopaedics, transplant, immune diseases, and genetic disorders.
Genzyme is also one of the largest providers of diagnostic testing services in the world and a major supplier of diagnostic products. The company is playing an important role in the movement toward personalized medicine by developing tests that can help physicians identify how patients are likely to respond to targeted therapies.
In oncology, Genzyme’s product development expertise, robust research program, and strong global infrastructure provide a solid base for developing and commercializing novel treatments for cancer patients. Genzyme currently has several promising oncology therapies in clinical trials, including treatments for chronic lymphocytic leukemia and pediatric acute lymphocytic leukemia. Among its current oncology products are Campath® (alemtuzumab) and Clolar® (clofarabine). Additional information for Campath may be obtained at www.campath.com and for Clolar at www.clolar.com. (Campath® and Clolar® are registered trademarks of Genzyme Corporation.)
Genzyme's ongoing discovery utilizes a broad range of target identification, target validation and drug development technologies, in active collaboration with select companies and academic institutions. Genzyme is striving to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments.
An innovative biotechnology company with a diverse portfolio of medical products, a deep scientific base with a truly global approach; a strong commitment to patients and community with a united sense of responsibility and shared values; a passion to solve problems that have not been solved; a drive to provide hope where there was none before—this is Genzyme.
TopoTarget USA, Inc.
TopoTarget USA, Inc.
TopoTarget USA, Inc.
100 Enterprise Drive
Rockaway, N.J. 07866
Tel: 973-895-6900
Fax: 973-328-2335
TopoTarget is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding "Answers for cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built.
TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget’s first product on the market.
TopoTarget USA will launch its first product through its own sales force supplemented by outsourced resources for distribution. Such a coordinated approach optimizes resource utilization while retaining profitability. The TopoTarget USA management team will work closely with TopoTarget's global team to maximize global launch success.
Facebook
LinkedIn
Twitter
ACCCExchange Listserve